图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
肿瘤形成评论综述™
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN 打印: 0893-9675
ISSN 在线: 2162-6448

肿瘤形成评论综述™

DOI: 10.1615/CritRevOncog.v17.i2.70
pages 233-246

Targeting the Human Kinome for Cancer Therapy: Current Perspectives

Luxi Zhang
Cancer Research Program, Garvan Institute of Medical Research
Roger J. Daly
St Vincent's Hospital Clinical School, Department of Medicine, University of New South Wales ; Cancer Research Program, Garvan Institute of Medical Research Sydney, New South Wales, Australia; Department of Biochemistry and Molecular Biology and Cancer Program, Biomedicine Discovery Institute, Monash University, VIC 3800, Australia

ABSTRACT

As highlighted by other articles in this review issue, great progress has been made in the development of targeted treatment modalities directed against particular oncogenic kinases, and the translation of these therapies into the clinic. However, recent data from cancer genome sequencing projects indicate that the spectrum of kinases that contribute to cancer progression is wider than previously imagined, and as international projects in this area gather momentum, it appears likely that further kinase oncogenes will be identified, and the roles of previously characterized ones will be extended to subsets of additional cancers. In addition, complementary approaches such as functional genomics and mass spectrometry (MS)-based proteomics are providing important insights into the functional roles played by specific kinases in particular cancers, the dependency of these roles on genetic background, how altered kinase regulation perturbs intracellular signaling networks, and how the latter respond to targeted agents that target the kinase in question. While other articles in this issue focus on individual cancer-associated kinases and their therapeutic targeting, the aim of this review is to take a broader perspective regarding our current knowledge of the cancer kinome and how this can be expanded and exploited for clinical utility.


Articles with similar content:

The Biology of Toll-Like Receptor 9 and Its Role in Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.30, 2020, issue 5
Badr Alzahrani
The Immune System in the Pathogenesis of Ovarian Cancer
Critical Reviews™ in Immunology, Vol.33, 2013, issue 2
Ellen L. Goode, Kimberly R. Kalli, Keith L. Knutson, Melissa S. DeRycke, Bridget Charbonneau
MicroRNAs: Cobblestones on the Road to Cancer Metastasis
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Valentina Profumo, Paolo Gandellini
Functional Role of MicroRNAs in Prostate Cancer and Therapeutic Opportunities
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Marcello Maugeri-Sacca, Valeria Coppola, Ruggero De Maria, Desiree Bonci
Src Kinase Inhibitors: Promising Cancer Therapeutics?
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Valerie G . Brunton, Helen Creedon